MedTrace Logo

A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.

NCT06306560 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-03-12

No results posted yet for this study

Summary

This is a single arm, multi-center, phase II trial to evaluate the efficacy, and safety of adebrelimab combined with famitinib and chemotherapy for the treatment of first-line extensive stage small cell lung cancer.

Conditions

  • Extensive-stage Small-cell Lung Cancer

Interventions

DRUG

adebrelimab

adebrelimab IV

DRUG

famitinib

famitinib PO

DRUG

chemotherapy

chemotherapy IV

Sponsors & Collaborators

  • Harbin Medical University

    lead OTHER

Principal Investigators

  • Yanbin Zhao, MD · Harbin Medical University Cancer Hosptital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-15
Primary Completion
2027-03-15
Completion
2027-04-15

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06306560 on ClinicalTrials.gov